Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs

被引:72
作者
Bhattacharya, Arup [1 ]
Seshadri, Mukund [1 ,2 ]
Oven, Steven D. [1 ]
Toth, Karoly [1 ]
Vaughan, Mary M. [3 ]
Rustum, Youcef M. [1 ]
机构
[1] Roswell Pk Canc Inst, Dept Canc Biol, Buffalo, NY 14263 USA
[2] Roswell Pk Canc Inst, Dept Preclin Imaging Resource, Buffalo, NY 14263 USA
[3] Roswell Pk Canc Inst, Pathol & Lab Med, Buffalo, NY 14263 USA
关键词
D O I
10.1158/1078-0432.CCR-08-0212
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Our previously reported therapeutic synergy between naturally occurring seleno-amino acid methylselenocysteine (MSC) and anticancer drugs could not be shown in vitro. Studies were carried out to investigate the potential role of MSC-induced tumor vascular maturation and increased drug delivery in the observed therapeutic synergy in vivo. Experimental Design: Mice bearing s.c. FaDu human head and neck squamous cell carcinoma xenografts were treated with MSC (0.2 mg/d x 14 days orally). Changes in microvessel density (CD31), vascular maturation (CD31/alpha-smooth muscle actin), perfusion (Hoechst 33342/DiOC(7)), and permeability (dynamic contrast-enhanced magnetic resonance imaging) were determined at the end of the 14-day treatment period. Additionally, the effect of MSC on drug delivery was investigated by determining intratumoral concentration of doxorubicin using high-performance liquid chromatography and fluorescence microscopy. Results: Double immunostaining of tumor sections revealed a marked reduction (similar to 40%) in microvessel density accompanying tumor growth inhibition following MSC treatment along with a concomitant increase in the vascular maturation index ( similar to 30% > control) indicative of increased pericyte coverage of microvessels. Hoechst 33342/DiOC(7) staining showed improved vessel functionality, and dynamic contrast-enhanced magnetic resonance imaging using the intravascular contrast agent, albumin-GdDTPA, revealed a significant reduction in vascular permeability following MSC treatment. Consistent with these observations, a 4-fold increase in intratumoral doxorubicin levels was observed with MSC pretreatment compared with administration of doxorubicin alone. Conclusion: These results show, for the first time, the antiangiogenic effects of MSC results in tumor growth inhibition, vascular maturation in vivo, and enhanced anticancer drug delivery that are associated with the observed therapeutic synergy in vivo.
引用
收藏
页码:3926 / 3932
页数:7
相关论文
共 27 条
[1]   Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy [J].
Bhattacharya, A ;
Tóth, K ;
Mazurchuk, R ;
Spernyak, JA ;
Siocum, HK ;
Pendyala, L ;
Azrak, R ;
Cao, SS ;
Durrani, FA ;
Rustum, YM .
CLINICAL CANCER RESEARCH, 2004, 10 (23) :8005-8017
[2]   Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts [J].
Cao, SS ;
Durrani, A ;
Rustum, YM .
CLINICAL CANCER RESEARCH, 2004, 10 (07) :2561-2569
[3]   Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin a randomized controlled trial - A randomized controlled trial [J].
Clark, LC ;
Combs, GF ;
Turnbull, BW ;
Slate, EH ;
Chalker, DK ;
Chow, J ;
Davis, LS ;
Glover, RA ;
Graham, GF ;
Gross, EG ;
Krongrad, A ;
Lesher, JL ;
Park, HK ;
Sanders, BB ;
Smith, CL ;
Taylor, JR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (24) :1957-1963
[4]   Chemopreventive agents: Selenium [J].
Combs, GF ;
Gray, WP .
PHARMACOLOGY & THERAPEUTICS, 1998, 79 (03) :179-192
[5]   Angiogenesis modulation in cancer research: Novel clinical approaches [J].
Cristofanilli, M ;
Charnsangavej, C ;
Hortobagyi, GN .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (06) :415-426
[6]   Revacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy [J].
Dickson, Paxton V. ;
Hamner, John B. ;
Sims, Thomas L. ;
Fraga, Charles H. ;
Ng, Catherine Y. C. ;
Rajasekeran, Surender ;
Hagedorn, Nikolaus L. ;
McCarville, M. Beth ;
Stewart, Clinton F. ;
Davidoff, Andrew M. .
CLINICAL CANCER RESEARCH, 2007, 13 (13) :3942-3950
[7]  
DURRANI F, 2007, P AACR
[8]   A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors [J].
Fakih, Marwan G. ;
Pendyala, Lakshmi ;
Brady, William ;
Smith, Patrick F. ;
Ross, Mary E. ;
Creaven, Patrick J. ;
Badmaev, Vladimir ;
Prey, Joshua D. ;
Rustum, Youcef M. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (03) :499-508
[9]   A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors [J].
Fakih, MG ;
Pendyala, L ;
Smith, PF ;
Creaven, PJ ;
Reid, ME ;
Badmaev, V ;
Azrak, RG ;
Prey, JD ;
Lawrence, D ;
Rustum, YM .
CLINICAL CANCER RESEARCH, 2006, 12 (04) :1237-1244
[10]  
FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182